<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01667029</url>
  </required_header>
  <id_info>
    <org_study_id>2012-p-001443</org_study_id>
    <nct_id>NCT01667029</nct_id>
  </id_info>
  <brief_title>Study of Sulfasalazine in Treating Painful Neuropathy</brief_title>
  <official_title>A Single-center, Randomized, Double-blind Clinical Study to Evaluate the Effect of Sulfasalazine on Painful Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that sulfasalazine, an FDA-approved medication for rheumatoid
      arthritis and ulcerative colitis, may be beneficial in neuropathic pain conditions. In this
      study, the investigators will evaluate whether sulfasalazine improves pain due to painful
      peripheral neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrollment
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 10, 2017</completion_date>
  <primary_completion_date type="Actual">August 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain score</measure>
    <time_frame>second week of two week treatment period</time_frame>
    <description>Average pain score will be the average of daily pain scores (0-10) recorded by the subject during the second week of the two week treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical Functioning Score</measure>
    <time_frame>Assessed at end of two week treatment period</time_frame>
    <description>Will be assessed using the Brief Pain Inventory Interference and Euroquality of Life metrics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional Functioning</measure>
    <time_frame>Assessed at end of two week treatment period</time_frame>
    <description>Will be assessed by the Beck Depression Inventory metric</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Improvement</measure>
    <time_frame>Will be assessed at end of two week treatment period</time_frame>
    <description>Will be assessed using the Patient Global Impression of Change metric</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical rating of pain intensity</measure>
    <time_frame>Assessed at end of two week treatment period</time_frame>
    <description>Assessed using description as &quot;none, mild, moderate, or severe&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breakthrough Treatment</measure>
    <time_frame>Assessed during two week treatment period</time_frame>
    <description>Number of times breakthrough pain medication was taken</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Painful Neuropathy</condition>
  <arm_group>
    <arm_group_label>sulfasalazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g oral twice daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo pill twice daily for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <arm_group_label>sulfasalazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Painful neuropathy

          -  Michigan Neuropathy Screening Instrument score of 3 or greater

          -  no obvious alternative explanation for neuropathy

          -  average baseline pain &gt; 4/10

        Exclusion Criteria:

          -  other severe pain

          -  anticipated difficulty weaning off medications

          -  past or current psychiatric disorder as determined by Mini International
             Neuropsychiatric Interview

          -  medical contraindication to sulfasalazine

          -  not proficient in English (due to heavy use of questionaires)

          -  pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J Wainger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Brian Wainger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

